📰 Hepatology Insights with Dr. Chetan R. Kalal

Global Updates | Expert Opinions | Transformative Care

🌐 Portal Hypertension (PHTN): 2025 Updates & Expert Perspective

By Dr. Chetan R. Kalal – Maharashtra’s First DM Hepatologist & Global Leader in Liver Transplant Medicine

Portal hypertension (PHTN) remains a central complication of chronic liver disease, driving ascites, variceal bleeding, and encephalopathy. Over the last decade, management has shifted from reactive to proactive, risk-stratified, non-invasive approaches.

🔥 What’s New in 2025?

• Non-Invasive Monitoring Now Mainstream

  • Elastography (FibroScan) combined with platelet count is now validated as a reliable predictor of clinically significant PHTN (per Baveno VII recommendations).

  • This spares many patients invasive HVPG measurements and helps triage who needs endoscopy.

• Beta-Blocker Therapy Expanded

  • Non-selective beta-blockers (NSBBs), including carvedilol, are recommended not only after variceal bleed but as primary prophylaxis in patients with CSPH.

  • Data show improved survival even in compensated cirrhosis when NSBBs are started early.

• Endoscopic & Interventional Advances

  • Endoscopic variceal ligation (EVL) remains gold standard for varices, but combination strategies with NSBBs show superior protection.

  • TIPS (Transjugular Intrahepatic Portosystemic Shunt) has seen refinements — covered stents and better patient selection improve long-term outcomes with fewer complications.

• Emerging Therapies

  • Ongoing trials are testing statins, GLP-1 agonists, and antifibrotic agents for their ability to reduce portal pressure and disease progression.

  • Immunotherapy and microbiome modulation are also being explored as adjuncts in cirrhosis and PHTN.

💡 Dr. Kalal’s Approach to PHTN

“Portal hypertension is no longer just about preventing variceal bleeds — it is about early detection, holistic risk reduction, and protecting liver reserve. By integrating FibroScan, NSBB prophylaxis, lifestyle/metabolic control, and timely interventional therapies, we can delay decompensation and improve survival.”

📌 Key Takeaways for Patients

• Get Screened Early: If you have fatty liver, cirrhosis, or chronic hepatitis, you may have silent portal hypertension.

• Non-Invasive Tools First: Modern tests like FibroScan + blood work can detect risk early without invasive procedures.

• Prevention Works: Medications like carvedilol can prevent first variceal bleeding events.

• Stay Connected: Regular follow-up with a liver specialist ensures optimal timing for interventions like EVL or TIPS.

🌍 Global Access with Dr. Chetan Kalal

• Virtual Consultations: 🇺🇸 USA | 🇬🇧 UK | 🇨🇦 Canada | 🇪🇺 Europe | 🇸🇬 Singapore | 🇦🇪 UAE | 🌍 Middle East & Africa | 🇦🇺 Australia | 🇳🇿 New Zealand

• In-Person Clinics: Andheri, Bandra (Pali Hill), Versova, Khar, Vile Parle – Mumbai

✨ Portal hypertension care has entered the era of precision hepatology — and Dr. Chetan Kalal ensures that patients in India and worldwide benefit from these advances.